Acute Lymphoblastic Leukemia (ALL): Symptoms, treatments, and expert care in Turkey

Acute Lymphoblastic Leukemia (ALL) is a fast-progressing blood cancer that requires rapid and precise medical intervention. It begins in the bone marrow, where immature white blood cells, called lymphoblasts, multiply uncontrollably. This overproduction disrupts normal blood cell formation and leaves the body vulnerable to infections, fatigue, and internal complications.

While ALL is most common in children, adults can also develop this disease and often face unique treatment challenges. Leading hospitals in Turkey, such as Biruni Hospital, provide care that goes beyond standard protocols. Treatment is individualized, combining medical precision with patient-centered support.

What is Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia is a type of cancer affecting the lymphoid line of white blood cells. Lymphoblasts grow rapidly, crowding out healthy blood cells and spreading through the bloodstream to organs such as the liver, spleen, and central nervous system. Without prompt treatment, ALL can become life-threatening in a matter of weeks.

Key features of ALL:

Rapidly affects lymphoid white blood cells
Originates in the bone marrow and spreads quickly
Inhibits normal blood cell production
Requires urgent, multi-phase treatment
Most common in children but also affects adults

Common symptoms of ALL:

Fatigue and weakness
Frequent infections
Bone or joint pain
Unexplained bruising or bleeding
Swollen lymph nodes or abdomen
Pale skin
Shortness of breath
Fever without clear cause

Treatment options for Acute Lymphoblastic Leukemia

Chemotherapy

Chemotherapy is the primary treatment for ALL. It uses powerful drugs to kill leukemia cells throughout the body, including the brain and spinal fluid, where leukemia cells may hide. Chemotherapy is given in phases: induction, consolidation, and maintenance.

Key steps in chemotherapy:

Induction phase to rapidly reduce leukemia cells
Consolidation phase to eliminate remaining cells
Maintenance phase to prevent relapse over months or years
Intrathecal chemotherapy to protect the brain and nervous system
Monitoring and managing side effects such as fatigue, nausea, and infections
Regular blood and bone marrow tests to track progress

Targeted Therapy (Smart Drugs)

Targeted therapy focuses on the specific weaknesses of leukemia cells, such as genetic mutations. For example, patients with the Philadelphia chromosome can benefit from drugs that block abnormal growth signals. Targeted therapy is often combined with chemotherapy and generally causes fewer side effects.

Key steps in targeted therapy:

Conducting genetic tests to identify treatment targets
Administering drugs that block leukemia cell growth signals
Monitoring effectiveness and side effects
Adjusting therapy if leukemia adapts

Immunotherapy

Immunotherapy trains the immune system to identify and attack leukemia cells. CAR T-cell therapy is an advanced approach in which a patient’s immune cells are collected, modified in a laboratory, and reintroduced to the body to target cancer cells. This therapy can be life-saving for patients who do not respond to other treatments.

Key steps in immunotherapy:

Collecting immune cells from the patient’s blood
Reprogramming cells to target leukemia
Preparing the patient with chemotherapy
Infusing modified cells into the bloodstream
Monitoring for side effects and immune response
Ongoing follow-up to evaluate effectiveness

Stem Cell Transplantation

Stem cell transplantation is used for high-risk or resistant ALL. The patient’s damaged bone marrow is destroyed with high-dose chemotherapy or radiation and replaced with healthy stem cells from a donor or previously collected from the patient.

Key steps in stem cell transplantation:

Evaluating patient suitability for transplant
Identifying a matching donor or using stored patient stem cells
Administering chemotherapy or radiation to remove leukemia
Infusing healthy stem cells to restore bone marrow function
Careful monitoring for complications such as infections or graft-versus-host disease
Long-term follow-up to prevent relapse and manage side effects

Smart drugs for Acute Lymphoblastic Leukemia

Smart drugs are advanced therapies that specifically target leukemia cells or help the body’s immune system fight the disease. They work differently from standard chemotherapy because they focus on precise features of cancer cells, which helps reduce damage to healthy cells. These treatments are especially important for patients whose leukemia has returned or has not responded to conventional therapy.

Blinatumomab (Blincyto)

Blinatumomab is a drug that helps the immune system directly attack leukemia cells. It works by connecting two types of cells: the patient’s T-cells (a type of immune cell that fights infections) and the leukemia cells.

How it works: Leukemia cells in ALL often have a protein called CD19 on their surface. Blinatumomab binds to CD19 and brings the T-cells close, activating them to destroy the leukemia cells.
Why it helps: This makes the patient’s own immune system fight the leukemia more effectively, even if chemotherapy alone is not working.
Administration: Given continuously through an IV over several weeks.
Use in ALL: Usually for patients whose disease has returned or did not respond to initial treatments.

Inotuzumab Ozogamicin (Besponsa)

Inotuzumab Ozogamicin is a drug that delivers a targeted poison directly into leukemia cells.

How it works: Many leukemia cells have a protein called CD22. The drug attaches to CD22 and releases a strong anti-cancer agent inside the cell, killing it.
Why it helps: It attacks only leukemia cells that have CD22, reducing harm to healthy cells.
Administration: Given through an IV in treatment cycles.
Use in ALL: For patients whose leukemia has returned or is resistant to other treatments.

Checkpoint Inhibitors (Experimental in ALL)

Checkpoint inhibitors are drugs that unlock the immune system to recognize leukemia cells. Normally, leukemia cells can hide from the immune system using special “off switches” like PD-1 or PD-L1 proteins. Checkpoint inhibitors block these switches so the immune system can see and attack the cancer.

How it works: It stops leukemia cells from hiding, letting T-cells do their job.
Why it helps: Can be used in advanced or hard-to-treat cases to strengthen the body’s natural defenses.
Use in ALL: Currently studied in clinical trials for patients with relapsed or refractory ALL.

Other Emerging Therapies

CAR T-cell therapy: A patient’s T-cells are collected and modified in the lab to specifically target leukemia cells, then returned to the body to attack the cancer.
Tyrosine kinase inhibitors (TKIs): These drugs block abnormal signals in leukemia cells that make them grow uncontrollably, particularly in Philadelphia chromosome-positive ALL.

Other types of Leukemia

Leukemia is not a single disease but a group of blood cancers that affect different types of blood cells. Each type has its own characteristics, progression speed, and treatment approaches. Understanding these variations can help patients and families better grasp the challenges and options for care.

Chronic Lymphocytic Leukemia (CLL)

CLL is a slow-progressing blood cancer that mainly affects adults. It starts in mature lymphocytes, a type of white blood cell, which gradually accumulate in the blood and bone marrow.

Because it develops slowly, symptoms such as swollen lymph nodes, fatigue, and frequent infections may appear gradually over months or years. Treatment often focuses on careful monitoring, controlling symptoms, and maintaining quality of life rather than immediate aggressive therapy.

Acute Myeloid Leukemia (AML)

AML is an aggressive and fast-growing leukemia that begins in the myeloid cell line, responsible for producing red blood cells, white blood cells, and platelets. The rapid overproduction of abnormal myeloid cells prevents the body from making healthy blood cells.

AML progresses quickly and requires urgent treatment, typically with high-dose chemotherapy, and sometimes stem cell transplantation. It is more commonly seen in adults and demands prompt medical intervention.

Chronic Myeloid Leukemia (CML)

CML is a type of leukemia that causes an overproduction of myeloid cells in the bone marrow. It often starts slowly, but if untreated, it can accelerate into a more dangerous phase.

CML is strongly linked to a genetic change called the Philadelphia chromosome, which causes abnormal cell growth. Targeted therapies that block this abnormal gene have dramatically improved outcomes, turning CML from a previously fatal disease into a manageable condition for many patients.

Hairy Cell Leukemia

Hairy cell leukemia is a rare, slow-growing chronic leukemia that affects B lymphocytes, a type of white blood cell. The disease gets its name from the fine, hair-like projections visible on the surface of abnormal cells under a microscopeb and It often causes fatigue, frequent infections, and an enlarged spleen.

Treatment usually involves chemotherapy or specialized targeted drugs, aiming to induce long-lasting remission while preserving quality of life.

Towards Healing

Acute lymphoblastic leukemia requires a personalized and multi-phase treatment approach. Chemotherapy, targeted therapy, immunotherapy, and stem cell transplantation each play a critical role in achieving remission.

With expert care in Turkey, particularly at specialized hospitals such as Biruni Hospital, patients benefit from precision medicine, comprehensive support, and advanced treatment options.

Understanding these therapies empowers patients and families to navigate the disease with clarity, confidence, and hope for a healthier future.